Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Availability Heuristic

The Availability Heuristic

A heuristic is a general problem-solving framework (Tversky & Kahneman, 1974). You can think of these as mental shortcuts that are used to solve problems. Different types of heuristics are used in different types of situations, and the impulse to use a heuristic occurs when one of five conditions is met (Pratkanis, 1989):

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026

Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026

Same author

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Breast (Edinburgh, Scotland)·2026

Same author

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer.

Breast (Edinburgh, Scotland)·2026

Same author

Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network.

JCO precision oncology·2026

Same author

Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer.

Molecular cancer·2026

Search research articles

Related Experiment Video

Updated: Mar 16, 2026

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

Published on: November 15, 2013

[Not Available].

Anthony Gonçalves¹

¹Département d'oncologie médicale, Institut Paoli-Calmettes, Marseille, 13009; Centre de recherche en cancérologie de Marseille (Institut Paoli-Calmettes, Inserm 1068, Cnrs 7258, Aix-Marseille Université), Marseille, 13009; Aix-Marseille Université, Marseille, 13006.

Bulletin Du Cancer

|August 7, 2016

Summary

This summary is machine-generated.

Neoadjuvant chemotherapy improves pathological complete response in HER2-positive and triple-negative breast cancers. Further research is needed to confirm if these improvements translate to better survival and breast conservation rates.

Keywords:

Breast cancer Cancer du sein Chimiothérapie HER2 Neoadjuvant Tripie-negative Triple-négatif chemotherapy néo-adjuvante

More Related Videos

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Published on: November 1, 2012

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

Published on: December 28, 2016

Related Experiment Videos

Last Updated: Mar 16, 2026

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

Published on: November 15, 2013

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Published on: November 1, 2012

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

Published on: December 28, 2016

Area of Science:

Oncology
Medical Oncology
Breast Cancer Research

Background:

Neoadjuvant chemotherapy is a standard treatment for operable breast cancer, offering survival benefits comparable to adjuvant chemotherapy.
It holds the potential to increase breast conservation rates.
Pathological complete response (pCR) in neoadjuvant therapy strongly predicts survival outcomes, particularly in HER2-positive and triple-negative breast cancers.

Purpose of the Study:

To review the efficacy of neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancers.
To evaluate the impact of novel therapeutic strategies on pCR rates.
To assess the long-term survival and breast conservation benefits of enhanced neoadjuvant regimens.

Main Methods:

Review of current clinical data and studies on neoadjuvant chemotherapy for HER2-positive and triple-negative breast cancers.
Analysis of pathological complete response rates associated with different chemotherapy regimens and targeted therapies.
Evaluation of survival data and breast conservation surgery rates in relevant patient cohorts.

Main Results:

Neoadjuvant chemotherapy significantly increases pCR in both HER2-positive and triple-negative breast cancers.
In HER2-positive breast cancer, dual HER2 blockade (e.g., pertuzumab-trastuzumab) further enhances pCR compared to trastuzumab monotherapy.
Incorporating platinum compounds into neoadjuvant chemotherapy regimens improves pCR in triple-negative breast cancer.

Conclusions:

Neoadjuvant chemotherapy, especially with targeted agents and platinum compounds, markedly improves pCR in HER2-positive and triple-negative breast cancers.
The clinical significance of these pCR improvements regarding long-term survival and increased rates of breast-conserving surgery requires further investigation.